Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
A phase 3 trial of Pemetrexed, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.
Overview
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation is a phase 3 interventional study registered as NCT06956001 by Allist Pharmaceuticals, Inc., with 300 participants planned, started 2024-11-19 and due to reach its primary completion in 2027-12. Interventions recorded: Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection, Carboplatin Injection. Conditions listed: EGFR, NSCLC (Advanced Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Shares Shanghai Allist Pharmaceuticals, Pemetrexed, Cisplatin, Carboplatin.
- TrialStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.